Sarepta, continuing its gene therapy push, helps launch a startup

BIOPHARMA DIVE, Oct. 22, 2020. AavantiBio joins a couple large, powerful companies in the hunt for a gene therapy to treat Friedreich's ataxia. Pfizer and Novartis are each working on their own programs. Outside of gene therapy, Reata Pharmaceuticals disclosed last year positive data from a study that tested an oral drug, known as omaveloxolone, in patients with Friedreich's ataxia. Reata said it intends to file the drug for approval based on those results.

Sarepta, continuing its gene therapy push, helps launch a startup